Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Merger agrmnt [a]
Quarterly results
CC transcript
Inv. presentation
Director departure
Appointed director
AMICUS THERAPEUTICS, INC. (FOLD) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/05/2023 8-K Termination of a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
10/02/2023 144 Form 144 - Report of proposed sale of securities:
10/02/2023 144 Form 144 - Report of proposed sale of securities:
10/02/2023 8-K Quarterly results
09/28/2023 8-K Quarterly results
09/27/2023 8-K Quarterly results
08/21/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer"
08/15/2023 144 Form 144 - Report of proposed sale of securities:
08/15/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom"
08/09/2023 144 Form 144 - Report of proposed sale of securities:
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Investor presentation, Quarterly results
Docs: "Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates",
"2 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and clinical trials, the prospects and timing of the potential regulatory approval of our product candidates, commercialization plans, manufacturing and supply plans, financing plans, and the projected revenues and cash position for the Company. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Any or all of the forward-looking statements in this presentation may turn out to be wrong and can be affected by inaccurate..."
08/01/2023 144 Form 144 - Report of proposed sale of securities:
08/01/2023 144 Form 144 - Report of proposed sale of securities:
07/17/2023 144 Form 144 - Report of proposed sale of securities:
07/13/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
07/12/2023 144 Form 144 - Report of proposed sale of securities:
07/03/2023 144 Form 144 - Report of proposed sale of securities:
07/03/2023 144 Form 144 - Report of proposed sale of securities:
06/06/2023 144 Form 144 - Report of proposed sale of securities:
06/01/2023 144 Form 144 - Report of proposed sale of securities:
06/01/2023 144 Form 144 - Report of proposed sale of securities:
05/12/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "2 to a given date, such representation and warranty shall be true and correct in all material respects as of such specified date); and both immediately before and immediately after giving effect to this Agreement, no Default or Event of Default shall have occurred and be continuing. 4. Representations and Warranties. Each of the Borrower and Parent hereby represents and warrants to the Agent and the Lenders that no Default or Event of Default has occurred and is continuing as of the date hereof, the representations and warranties made by the Borrower and Parent contained in the Loan Documents are true and correct in all material respects as of the date hereof, except to the extent such representation or warranty expressly relates to an earlier date , the execution, delivery and performance..."
05/10/2023 8-K Investor presentation, Quarterly results
Docs: "Amicus Therapeutics, Inc. Consolidated Statements of Operations Three Months Ended March 31, 2023 2022 Net product sales $ 86,270 $ 78,715 Cost of goods sold 6,942 7,582 Gross profit 79,328 71,133 Operating expenses: Research and development 41,499 81,517 Selling, general, and administrative 73,957 58,116 Changes in fair value of contingent consideration payable 251 Loss on impairment of assets — 6,616 Depreciation and amortization 1,257 1,411 Total operating expenses 116,964 146,472 Loss from operations Other income: Interest income 2,199 133 Interest expense Other income 1,902 Loss before income tax Income tax benefit 287 Net loss attributable to common stockholders $ $ Net loss attributable to common stockholders per common share — basic and diluted $ $ Weighted-average common share...",
"2 Forward-Looking Statements This presentation contains"forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and clinical trials, the prospects and timing of the potential regulatory approval of our product candidates, commercialization plans, manufacturing and supply plans, financing plans, and the projected revenues and cash position for the Company. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Any or all of the forward-looking statements in this presentation may turn out to be wrong and can be affected by inaccurate ..."
05/01/2023 144 Form 144 - Report of proposed sale of securities:
05/01/2023 144 Form 144 - Report of proposed sale of securities:
04/26/2023 ARS Form ARS - Annual Report to Security Holders:
04/26/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/26/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/26/2023 8-K Quarterly results
04/24/2023 8-K Quarterly results
04/14/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/27/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Amicus Therapeutics Announces European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease"
03/01/2023 10-K Annual Report for the period ended December 31, 2022
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy